Cargando…

Measures to mitigate disruption due to the COVID-19 pandemic of the MODIFY phase 3 pivotal trial in patients with Fabry disease

Detalles Bibliográficos
Autores principales:	Frey, Aline, Trokan, Luba, Vogler, Markus, Hughes, Derralynn, Gimona, Alberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academic Press 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849486/ http://dx.doi.org/10.1016/j.ymgme.2020.12.080

Ejemplares similares

Understanding and modifying Fabry disease: Rationale and design of a pivotal Phase 3 study and results from a patient-reported outcome validation study
por: Wanner, Christoph, et al.
Publicado: (2022)

Fabry disease and incidence of cancer
por: Bird, Sarah, et al.
Publicado: (2017)

Toward a consensus in the laboratory diagnostics of Fabry disease - recommendations of a European expert group
por: Gal, Andreas, et al.
Publicado: (2011)

Pathologic findings of Fabry nephropathy: the pivotal role of kidney biopsy
por: Shin, Jung-ho, et al.
Publicado: (2021)

Clinical prodromes of neurodegeneration in Anderson-Fabry disease
por: Löhle, Matthias, et al.
Publicado: (2015)

Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis
por: Beck, Michael, et al.
Publicado: (2015)

Estimation of Health State Utility Values in Fabry Disease Using Vignette Development and Valuation
por: Hughes, Derralynn, et al.
Publicado: (2023)

A Novel Rapid MALDI-TOF-MS-Based Method for Measuring Urinary Globotriaosylceramide in Fabry Patients
por: Alharbi, Fahad J., et al.
Publicado: (2016)

Prevalence of CADASIL and Fabry Disease in a Cohort of MRI Defined Younger Onset Lacunar Stroke
por: Kilarski, Laura L., et al.
Publicado: (2015)

Consensus recommendations for the treatment and management of patients with Fabry disease on migalastat: a modified Delphi study
por: Bichet, Daniel G., et al.
Publicado: (2023)

Prompt Agalsidase Alfa Therapy Initiation is Associated with Improved Renal and Cardiovascular Outcomes in a Fabry Outcome Survey Analysis
por: Hughes, Derralynn, et al.
Publicado: (2021)

Do clinical guidelines facilitate or impede drivers of treatment in Fabry disease?
por: Hughes, Derralynn A., et al.
Publicado: (2022)

Cardiac Phenotype of Prehypertrophic Fabry Disease
por: Nordin, Sabrina, et al.
Publicado: (2018)

Biomarkers of Myocardial Fibrosis: Revealing the Natural History of Fibrogenesis in Fabry Disease Cardiomyopathy
por: Aguiar, Patrício, et al.
Publicado: (2018)

Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb(3)) in Fabry Transgenic Mice and in the Plasma of Fabry Patients
por: Young-Gqamana, Brandy, et al.
Publicado: (2013)

Cardiac device implantation and device usage in Fabry and hypertrophic cardiomyopathy
por: Vijapurapu, Ravi, et al.
Publicado: (2022)

Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study
por: Hughes, Derralynn A., et al.
Publicado: (2019)

Long-term follow-up of renal function in patients treated with migalastat for Fabry disease
por: Bichet, Daniel G., et al.
Publicado: (2021)

Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trial
por: Schiffmann, Raphael, et al.
Publicado: (2018)

Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study
por: Arends, Maarten, et al.
Publicado: (2017)

Study of indications for cardiac device implantation and utilisation in Fabry cardiomyopathy
por: Vijapurapu, Ravi, et al.
Publicado: (2019)

Management of pain in Fabry disease in the UK clinical setting: consensus findings from an expert Delphi panel
por: Stepien, Karolina M., et al.
Publicado: (2023)

Polaritons in modified Fabry–Perot cavities and entanglement
por: Chernyak, Vladimir Y.
Publicado: (2023)

Safety and pharmacodynamic effects of a pharmacological chaperone on α-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies
por: Germain, Dominique P, et al.
Publicado: (2012)

The myocardial phenotype of Fabry disease pre-hypertrophy and pre-detectable storage
por: Augusto, João B, et al.
Publicado: (2020)

Systematic review of the incidence and clinical risk predictors of atrial fibrillation and permanent pacemaker implantation for bradycardia in Fabry disease
por: Vijapurapu, Ravi, et al.
Publicado: (2023)

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
por: Linhart, Aleš, et al.
Publicado: (2023)

The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat
por: Benjamin, Elfrida R., et al.
Publicado: (2017)

Phase Shift Effects in Fabry-Perot Interferometry
por: Koester, Charles J.
Publicado: (1960)

Disruptions to schistosomiasis programmes due to COVID-19: an analysis of potential impact and mitigation strategies
por: Kura, Klodeta, et al.
Publicado: (2021)

Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factors
por: Arends, Maarten, et al.
Publicado: (2017)

A Distinct Urinary Biomarker Pattern Characteristic of Female Fabry Patients That Mirrors Response to Enzyme Replacement Therapy
por: Kistler, Andreas D., et al.
Publicado: (2011)

Myocardial Storage, Inflammation, and Cardiac Phenotype in Fabry Disease After One Year of Enzyme Replacement Therapy
por: Nordin, Sabrina, et al.
Publicado: (2019)

Symptoms and Quality of Life in Patients with Fabry Disease: Results from an International Patient Survey
por: Morand, Olivier, et al.
Publicado: (2019)

Cardio- Renal Outcomes With Long- Term Agalsidase Alfa Enzyme Replacement Therapy: A 10- Year Fabry Outcome Survey (FOS) Analysis
por: Ramaswami, Uma, et al.
Publicado: (2019)

Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document
por: Biegstraaten, Marieke, et al.
Publicado: (2015)

Impact of Strategies for Mitigating Delays and Disruptions in Cancer Care Due to COVID-19: Systematic Review
por: Pacheco, Rafael Leite, et al.
Publicado: (2021)

Fasting mitigates immediate hypersensitivity: a pivotal role of endogenous D-beta-hydroxybutyrate
por: Nakamura, Shigeru, et al.
Publicado: (2014)

Long-term multisystemic efficacy of migalastat on Fabry-associated clinical events, including renal, cardiac and cerebrovascular outcomes
por: Hughes, Derralynn A, et al.
Publicado: (2023)

Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
por: Arends, Maarten, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_s9qkrq9bv0srgd02evmkavtcsf